

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB 3/28/2008
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

BRAF Codon 600 Mutation Detection by Pyrosequencing

ARUP test code 2002498

BRAF Codon 600 Mutation Detection

Not Detected

A mutation in BRAF codon 600 was not detected.

This result has been reviewed and approved by [REDACTED]

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: BRAF Codon 600 Mutation Detection by Pyrosequencing

Interpretation of BRAF test results depends on the tissue tested (colorectal carcinoma, papillary thyroid carcinoma, melanoma, or other tumors).

COLORECTAL CARCINOMA

In a microsatellite unstable colorectal carcinoma a BRAF c.1799T>A, p.Val600Glu (V600E) mutation indicates that the tumor is probably sporadic and not associated with Lynch syndrome (HNPCC). However, if a BRAF mutation is not detected, the tumor may either be sporadic or Lynch syndrome associated.

Detection of BRAF mutations may also be useful in determining patient eligibility for anti-EGFR treatment.

THYROID TUMORS

In papillary thyroid carcinoma a BRAF c.1799T>A, p.Val600Glu (V600E) mutation is highly specific and is only rarely associated with other well-differentiated thyroid neoplasms or nodular goiters.

MELANOMAS AND OTHER TUMORS

Mutations in BRAF codon 600 may indicate whether a tumor is likely to respond to therapy that targets the BRAF pathway.

Methodology:

DNA is isolated from microdissected tumor tissue and amplified for exon 15 of the BRAF gene. Mutation status is determined by pyrosequencing.

Limitations: Mutations in other locations within the BRAF gene or in other genes will not be detected.

Limit of detection: 10 percent mutant alleles.

Clinical Disclaimer: Results of this test must always be interpreted within the clinical context and other relevant data, and should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

Block ID

S19-24314 A1

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-331-401129
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 3 | Printed: 1/29/2021 6:39:40 AM
4848

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
BRAF Codon 600 Mutation Detection	19-331-401129	11/26/2019 3:28:00 PM	11/28/2019 6:50:28 AM	12/2/2019 11:34:00 AM
Block ID	19-331-401129	11/26/2019 3:28:00 PM	11/28/2019 6:50:28 AM	11/28/2019 7:52:00 AM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-331-401129
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 1/29/2021 6:39:40 AM
4848